<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: financial condition liquidity", fill: "#cfcfc4"},
{source: "2: financial condition liquidity", target: "2: operations could", fill: "#cfcfc4"},
{source: "2: operations could", target: "2: materially adversely affected by", fill: "#cfcfc4"},
{source: "2: financial condition liquidity", target: "6: product sales", fill: "#808080"},
{source: "6: product sales", target: "6: adversely affected by", fill: "#808080"},
{source: "6: adversely affected by", target: "6: competitors", fill: "#808080"},
{source: "6: competitors", target: "6: marketplace by generic versions", fill: "#808080"},
{source: "6: marketplace by generic versions", target: "6: same therapeutic", fill: "#808080"},
{source: "6: product sales", target: "10: necessary", fill: "#915f6d"},
{source: "10: necessary", target: "10: investments", fill: "#915f6d"},
{source: "10: investments", target: "10: development", fill: "#915f6d"},
{source: "10: development", target: "10: expenditures", fill: "#915f6d"},
{source: "10: expenditures", target: "10: bring new drugs", fill: "#915f6d"},
{source: "10: necessary", target: "11: no major patent expirations", fill: "#49796b"},
{source: "11: no major patent expirations", target: "11: decade but several", fill: "#49796b"},
{source: "11: no major patent expirations", target: "13: In the US the HatchWaxman Act ", fill: "#8b0000"},
{source: "13: In the US the HatchWaxman Act ", target: "13: generic companies powerful incentives", fill: "#8b0000"},
{source: "13: generic companies powerful incentives", target: "13: patents as", fill: "#8b0000"},
{source: "13: patents as", target: "13: patents on major products will", fill: "#8b0000"},
{source: "13: patents on major products will", target: "13: routinely challenged", fill: "#8b0000"},
{source: "13: routinely challenged", target: "13: patents will", fill: "#8b0000"},
{source: "13: In the US the HatchWaxman Act ", target: "15: addition competitors", fill: "#eae0c8"},
{source: "15: addition competitors", target: "15: third parties may", fill: "#eae0c8"},
{source: "15: third parties may", target: "15: activities infringe patents", fill: "#eae0c8"},
{source: "15: activities infringe patents", target: "15: intellectual property rights", fill: "#eae0c8"},
{source: "15: addition competitors", target: "17: increasing government price controls", fill: "#ffba00"},
{source: "17: increasing government price controls", target: "17: health care cost containment measures", fill: "#ffba00"},
{source: "17: increasing government price controls", target: "18: Government ", fill: "#df73ff"},
{source: "18: Government ", target: "18: health care", fill: "#df73ff"},
{source: "18: health care", target: "18: significantly affect", fill: "#df73ff"},
{source: "18: significantly affect", target: "18: profitability", fill: "#df73ff"},
{source: "18: Government ", target: "19: countries outside", fill: "#a0d6b4"},
{source: "19: countries outside", target: "19: United States ", fill: "#a0d6b4"},
{source: "19: United States ", target: "19: government", fill: "#a0d6b4"},
{source: "19: government", target: "19: agencies strictly control directly", fill: "#a0d6b4"},
{source: "19: agencies strictly control directly", target: "19: indirectly", fill: "#a0d6b4"},
{source: "19: indirectly", target: "19: prices at which", fill: "#a0d6b4"},
{source: "19: countries outside", target: "24: difficulties", fill: "#843f5b"},
{source: "24: difficulties", target: "24: uncertainties inherent", fill: "#843f5b"},
{source: "24: uncertainties inherent", target: "24: new product development", fill: "#843f5b"},
{source: "24: new product development", target: "24: introduction", fill: "#843f5b"},
{source: "24: introduction", target: "24: new products", fill: "#843f5b"},
{source: "24: difficulties", target: "25: product candidates", fill: "#ce2029"},
{source: "25: product candidates", target: "25: development", fill: "#ce2029"},
{source: "25: development", target: "25: commercial success", fill: "#ce2029"},
{source: "25: commercial success", target: "25: safety concerns inability", fill: "#ce2029"},
{source: "25: safety concerns inability", target: "25: necessary regulatory approvals", fill: "#ce2029"},
{source: "25: necessary regulatory approvals", target: "25: approved uses", fill: "#ce2029"},
{source: "25: approved uses", target: "25: difficulty", fill: "#ce2029"},
{source: "25: difficulty", target: "25: excessive costs", fill: "#ce2029"},
{source: "25: excessive costs", target: "25: manufacture", fill: "#ce2029"},
{source: "25: manufacture", target: "25: infringement", fill: "#ce2029"},
{source: "25: infringement", target: "25: intellectual property rights", fill: "#ce2029"},
{source: "25: product candidates", target: "32: unexpected steep", fill: "#e3256b"},
{source: "32: unexpected steep", target: "32: extended decline", fill: "#e3256b"},
{source: "32: extended decline", target: "32: unexpected safety", fill: "#e3256b"},
{source: "32: unexpected safety", target: "32: regulatory action", fill: "#e3256b"},
{source: "32: regulatory action", target: "32: premature loss", fill: "#e3256b"},
{source: "32: premature loss", target: "32: patent protection could", fill: "#e3256b"},
{source: "32: patent protection could", target: "32: adverse impact on", fill: "#e3256b"},
{source: "32: adverse impact on", target: "32: operations financial condition", fill: "#e3256b"},
{source: "32: unexpected steep", target: "33: Regulatory ", fill: "#cd853f"},
{source: "33: Regulatory ", target: "33: compliance failures could", fill: "#cd853f"},
{source: "33: Regulatory ", target: "34: pharmaceutical", fill: "#534b4f"},
{source: "34: pharmaceutical", target: "34: manufacturers as well as", fill: "#534b4f"},
{source: "34: manufacturers as well as", target: "34: which manufacturers interact with", fill: "#534b4f"},
{source: "34: which manufacturers interact with", target: "34: prescribers", fill: "#534b4f"},
{source: "34: pharmaceutical", target: "37: Managements Discussion ", fill: "#a67b5b"},
{source: "37: Managements Discussion ", target: "37: discussions", fill: "#a67b5b"},
{source: "37: discussions", target: "37: marketing practices investigations", fill: "#a67b5b"},
{source: "37: Managements Discussion ", target: "38: addition regulatory", fill: "#ffe5b4"},
{source: "38: addition regulatory", target: "38: Good Manufacturing Practice ", fill: "#ffe5b4"},
{source: "38: Good Manufacturing Practice ", target: "38: regulations", fill: "#ffe5b4"},
{source: "38: regulations", target: "38: pharmaceutical products", fill: "#ffe5b4"},
{source: "38: pharmaceutical products", target: "38: product recalls", fill: "#ffe5b4"},
{source: "38: product recalls", target: "38: seizures interruption", fill: "#ffe5b4"},
{source: "38: seizures interruption", target: "38: production leading", fill: "#ffe5b4"},
{source: "38: production leading", target: "38: product shortages", fill: "#ffe5b4"},
{source: "38: product shortages", target: "38: new products pending resolution", fill: "#ffe5b4"},
{source: "38: addition regulatory", target: "START_HERE", fill: "#ffe5b4"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gaussian_elimination">Gaussian elimination</a></td>
      <td>In mathematics, Gaussian elimination, also known as row reduction, is an algorithm for solving systems of linear equations. It consists of a sequence of operations performed on the corresponding matrix of coefficients.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gordon_v._Virtumundo,_Inc.">Gordon v. Virtumundo, Inc.</a></td>
      <td>Gordon v. Virtumundo, Inc., 575 F.3d 1040, is a 2009 court opinion in which the United States Court of Appeals for the Ninth Circuit addressed the standing requirements necessary for private plaintiffs to bring suit under the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003, or CAN-SPAM Act of 2003, 15 U.S.C. ch.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unreal_Engine">Unreal Engine</a></td>
      <td>Unreal Engine (UE) is a 3D computer graphics game engine developed by Epic Games, first showcased in the 1998 first-person shooter game Unreal. Initially developed for PC first-person shooters, it has since been used in a variety of genres of games and has seen adoption by other industries, most notably the film and television industry.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Anatomical_Therapeutic_Chemical_Classification_System">Anatomical Therapeutic Chemical Classification System</a></td>
      <td>The Anatomical Therapeutic Chemical (ATC) Classification System is a drug classification system that classifies the active ingredients of drugs according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties. Its purpose is an aid to monitor drug use and for research to improve quality medication use.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vivek_Murthy">Vivek Murthy</a></td>
      <td>Vivek Hallegere Murthy (born July 10, 1977) is an American physician and a vice admiral in the United States Public Health Service Commissioned Corps who has served as the 19th and 21st surgeon general of the United States under President Obama and President Biden. Murthy is the first surgeon general of Indian descent, and, during his first term as surgeon general, he was the youngest active duty flag officer in federal uniformed service.Murthy co-chaired President-elect Joe Biden's COVID-19 Advisory Board from November 2020 to January 2021, alongside former Food and Drug Administration commissioner David A. Kessler and Yale public health professor Marcella Nunez-Smith.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Designer_drug">Designer drug</a></td>
      <td>A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Designer drugs include psychoactive substances that have been designated by the European Union as new psychoactive substances (NPS) as well as analogs of performance-enhancing drugs such as designer steroids.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nanjing_decade">Nanjing decade</a></td>
      <td>The Nanjing decade (also Nanking decade, Chinese: 南京十年; pinyin: Nánjīng shí nián, or the Golden decade, Chinese: 黃金十年; pinyin: Huángjīn shí nián) is an informal name for the decade from 1927 (or 1928) to 1937 in the Republic of China.  It began when Nationalist Generalissimo Chiang Kai-shek took Nanjing from Zhili clique warlord Sun Chuanfang halfway through the Northern Expedition in 1927.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Katelyn_Ohashi">Katelyn Ohashi</a></td>
      <td>Katelyn Michelle Ohashi (born April 12, 1997) is an American former artistic gymnast who competed for the University of California, Los Angeles. She is a six-time All-American and was a four-time member of USA Gymnastics' Junior National Team, the 2011 junior national champion and the winner of the 2013 American Cup.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Novelty_(patent)">Novelty (patent)</a></td>
      <td>Novelty is a requirement for a patent claim to be patentable. An invention is not new and therefore not patentable if it was known to the public before the filing date of the patent application, or before its date of priority if the applicant claims priority of an earlier patent application.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/COVID-19_pandemic">COVID-19 pandemic</a></td>
      <td>The COVID-19 pandemic, also known as the coronavirus pandemic, is an ongoing global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The novel virus was first identified from an outbreak in Wuhan, China, in December 2019.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government_of_India">Government of India</a></td>
      <td>The Government of India (ISO: Bhārat Sarkār) (often abbreviated as GoI; also known as the Central or Union Government), or simply the Centre, is the federal governing authority of the Republic of India created by the Constitution of India as the legislative, executive and judicial authority to govern the union of twenty eight states and eight union territories. The president acts as the head of state and is the highest figure of authority, nominally, of the nation however it is the prime minister who is the chief executive.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_Profitability_Analysis">Customer Profitability Analysis</a></td>
      <td>Customer Profitability Analysis (in short CPA) is a management accounting and a credit underwriting method, allowing businesses and lenders to determine the profitability of each customer or segments of customers, by attributing profits and costs to each customer separately. CPA can be applied at the individual customer level (more time consuming, but providing a better understanding of business situation) or at the level of customer aggregates / groups (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government_of_Canada">Government of Canada</a></td>
      <td>The government of Canada (French: gouvernement du Canada) is the body responsible for the federal administration of Canada. A constitutional monarchy, the Crown is the corporation sole, assuming distinct roles: the executive, as the Crown-in-Council; the legislature, as the Crown-in-Parliament; and the courts, as the Crown-on-the-Bench.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Agenzia_Informazioni_e_Sicurezza_Esterna">Agenzia Informazioni e Sicurezza Esterna</a></td>
      <td>The Agenzia Informazioni e Sicurezza Esterna (AISE; Italian: External Intelligence and Security Agency) is the foreign intelligence service of Italy. \nAISE was established in 2007 to replace the Military Intelligence and Security Service (SISMI) as part of reforms of Italy's intelligence services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_product_development">Collaborative product development</a></td>
      <td>Collaborative product development (collaborative product design)  (CPD) is a business strategy, work process and collection of software applications that facilitates different organizations to work together on the development of a product. It is also known as collaborative product definition management (cPDM).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nani_(actor)">Nani (actor)</a></td>
      <td>Ghanta Naveen Babu (born 24 February 1984), known professionally as Nani, is an Indian actor, producer, and television presenter primarily known for his work in Telugu cinema. Nani made his film debut with the 2008 romantic comedy Ashta Chamma and went on to star in many commercially successful films.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Population_decline">Population decline</a></td>
      <td>A population decline (also sometimes called underpopulation, depopulation, or population collapse) in humans is a reduction in a human population size. Over the long term, stretching from prehistory to the present, Earth's total human population has continued to grow; however, current projections suggest that this long-term trend of steady population growth may be coming to an end.Until the beginning of the Industrial Revolution, global population grew very slowly.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bupa">Bupa</a></td>
      <td>A pupa (Latin: pupa, "doll"; plural: pupae) is the life stage of some insects undergoing transformation between immature and mature stages. Insects that go through a pupal stage are holometabolous: they go through four distinct stages in their life cycle, the stages thereof being egg, larva, pupa, and imago.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sen_Çal_Kapımı">Sen Çal Kapımı</a></td>
      <td>Sen Çal Kapımı (known as Love is in the Air in other territories) is a Turkish television series starring Hande Erçel and Kerem Bürsin. It premiered on Fox on July 8, 2020 and concluded on September 8, 2021.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cherubism">Cherubism</a></td>
      <td>Cherubism is a rare genetic disorder that causes prominence in the lower portion in the face. The name is derived from the temporary chubby-cheeked resemblance to putti, often confused with cherubs, in Renaissance paintings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/History_of_patent_law">History of patent law</a></td>
      <td>The history of patents and patent law is generally considered to have started with the Venetian Statute of 1474.\n\n\n== Early precedents ==\nThere is some evidence that some form of patent rights was recognized in Ancient Greece.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Nikola_Tesla_patents">List of Nikola Tesla patents</a></td>
      <td>Nikola Tesla was an inventor who obtained around 300 patents worldwide for his inventions. Some of Tesla's patents are not accounted for, and various sources have discovered some that have lain hidden in patent archives.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Copyright">Copyright</a></td>
      <td>A copyright is a type of intellectual property that gives its owner the exclusive right to copy and distribute a creative work, usually for a limited time. The creative work may be in a literary, artistic, educational, or musical form.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/D-8_Organization_for_Economic_Cooperation">D-8 Organization for Economic Cooperation</a></td>
      <td>The D-8 Organization for Economic Cooperation, also known as Developing-8, is an organisation for development co-operation among the following countries: Bangladesh, Egypt, Indonesia, Iran, Malaysia, Nigeria, Pakistan, and Turkey. The objectives of D-8 Organization for Economic Cooperation are to improve member states' position in the global economy, diversify and create new opportunities in trade relations, enhance participation in decision-making at international level, and improve standards of living.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Compliance_Inspection">Compliance Inspection</a></td>
      <td>Unit Compliance Inspection (UCI) is a United States Air Force inspection conducted to assess areas mandated by law, as well as mission areas identified by senior Air Force and Major Command (MAJCOM) leadership as critical or important to the health and performance of a unit. Failure to comply with established directives in these areas could result in significant legal liabilities, penalties, or significant mission impact.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Programmable_logic_controller">Programmable logic controller</a></td>
      <td>A programmable logic controller (PLC) or programmable controller is an industrial computer that has been ruggedized and adapted for the control of manufacturing processes, such as assembly lines, machines, robotic devices, or any activity that requires high reliability, ease of programming, and process fault diagnosis. Dick Morley is considered as the father of PLC as he had invented the first PLC, the Modicon 084, for General Motors in 1968.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Valdai_Discussion_Club">Valdai Discussion Club</a></td>
      <td>The Valdai Discussion Club is a Moscow-based think tank and discussion forum that is closely associated with President Vladimir Putin, and that been described by Western commentators as part of the Russian propaganda effort. It was established in 2004 and is named after Lake Valdai, which is located close to Veliky Novgorod, where the Club’s first meeting took place.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Discussion_group">Discussion group</a></td>
      <td>A discussion group is a group of individuals, typically who share a similar interest, who gather either formally or informally to discuss ideas, solve problems, or make comments. Common methods of conversing including meeting in person, conducting conference calls, using text messaging, or using a website such as an Internet forum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Self-regulatory_organization">Self-regulatory organization</a></td>
      <td>A self-regulatory organization (SRO) is an organization that exercises some degree of regulatory authority over an industry or profession. The regulatory authority could exist in place of government regulation, or applied in addition to government regulation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vehicle_emission_standard">Vehicle emission standard</a></td>
      <td>Emission standards  are the legal requirements governing air pollutants released into the atmosphere. Emission standards set quantitative limits on the permissible amount of specific air pollutants that may be released from specific sources over specific timeframes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_largest_selling_pharmaceutical_products">List of largest selling pharmaceutical products</a></td>
      <td>\n== Best selling pharmaceuticals of U.S. Market ==\nThe top 5 best selling pharmaceuticals 2015-2019. Sales in billion USD.\n\n\n== Best selling pharmaceuticals of 2017/18 ==\nThe top 16 best selling pharmaceuticals of 2017/18.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/White_Rabbit_(candy)">White Rabbit (candy)</a></td>
      <td>White Rabbit Creamy Candy (Chinese: 大白兔奶糖; pinyin: Dàbáitù Nǎitáng) is a brand of milk candy manufactured by Shanghai Guan Sheng Yuan Food, Ltd. (Chinese: 上海冠生园食品有限公司; pinyin: Shànghǎi Guānshēngyuán Shípǐn Yǒuxiàn Gōngsī), in China.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Seizure_types">Seizure types</a></td>
      <td>Seizure types most commonly follow the classification proposed by the International League Against Epilepsy (ILAE) in 1981. These classifications have been updated in 2017.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Saint_(TV_series)">The Saint (TV series)</a></td>
      <td>The Saint is a British mystery spy thriller television series that aired in the United Kingdom on ITV between 1962 and 1969. It was based on the literary character Simon Templar created by Leslie Charteris in the 1920s and featured in many novels over the years.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>LILLY ELI &amp; CO      Item 1A               Risk Factors       In  addition to the other information contained in this Form 10-K, the     <font color="blue">following risk factors should</font> be considered <font color="blue">carefully</font> in evaluating our     company</td>
    </tr>
    <tr>
      <td>It is possible that our business, financial condition, liquidity or     results of <font color="blue">operations could</font> be <font color="blue">materially <font color="blue">adversely affected by</font></font> any of these     risks</td>
    </tr>
    <tr>
      <td>11       _________________________________________________________________    [59]Table of Contents       • We <font color="blue">face intense competition</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with</font> large number of <font color="blue">multinational</font>     <font color="blue">pharmaceutical</font> companies, biotechnology companies and <font color="blue">generic <font color="blue">pharmaceutical</font></font>     companies</td>
    </tr>
    <tr>
      <td>To <font color="blue">compete successfully</font>, we <font color="blue">must continue</font> to deliver to the     market innovative, cost-effective products that <font color="blue">meet important medical</font>     needs</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product sales</font> can be <font color="blue">adversely affected by</font> the <font color="blue">introduction</font> by     <font color="blue">competitors</font> of branded products that are perceived as superior by the     marketplace, by generic versions of our branded products, and by generic     versions of other products in the <font color="blue">same therapeutic</font> class as our branded     products</td>
    </tr>
    <tr>
      <td>Our     long-term success depends on our ability to <font color="blue">continually discover</font>, develop,     and <font color="blue">commercialize innovative new <font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>Without strong     intellectual property protection, we would be unable to generate the returns     <font color="blue">necessary</font> to support the enormous <font color="blue">investments</font> in research and <font color="blue">development</font>,     capital, and other <font color="blue">expenditures</font> required to <font color="blue">bring new drugs</font> to the market</td>
    </tr>
    <tr>
      <td>We currently expect <font color="blue">no major patent expirations</font> in this decade, but several     major products will lose intellectual property protection in the first half     of the next decade</td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font><font color="blue">property protection varies throughout</font> the world and is     subject to change over time</td>
    </tr>
    <tr>
      <td>In the US, the Hatch-Waxman Act provides     <font color="blue">generic companies powerful incentives</font> to seek to invalidate our patents; as     a result, we expect that our US <font color="blue">patents on major products will</font> be     <font color="blue">routinely challenged</font>, and there can be no assurance that our <font color="blue">patents will</font> be     upheld</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">competitors</font> or other     <font color="blue">third parties may</font> claim that our <font color="blue">activities infringe patents</font> or other     <font color="blue">intellectual property rights</font> held by them</td>
    </tr>
    <tr>
      <td>If successful, such claims could     result in our being unable to market a product in a <font color="blue">particular territory</font> or     being required to pay damages for <font color="blue">past <font color="blue">infringement</font></font> or <font color="blue">royalties on future</font>     sales</td>
    </tr>
    <tr>
      <td>• Our business is subject to <font color="blue">increasing <font color="blue">government</font> price controls</font> and other     <font color="blue"><font color="blue">health care</font> cost containment measures</font></td>
    </tr>
    <tr>
      <td><font color="blue">Government </font><font color="blue">health care</font>     cost-containment measures can <font color="blue">significantly affect</font> our sales and     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>In many <font color="blue">countries outside</font> the United States, <font color="blue">government</font>     agencies strictly control, directly or <font color="blue">indirectly</font>, the <font color="blue">prices at which</font> our     products are sold</td>
    </tr>
    <tr>
      <td>In the United States, we are subject to substantial     <font color="blue"><font color="blue">pricing pressures</font> from</font> state Medicaid programs and <font color="blue">private insurance</font>     programs, including those operating under the new Medicare <font color="blue">pharmaceutical</font>     <font color="blue">benefit effective</font> January 2006</td>
    </tr>
    <tr>
      <td>We expect <font color="blue">pricing pressures</font> to increase</td>
    </tr>
    <tr>
      <td>See     Item I, “Business — Regulations Affecting <font color="blue">Pharmaceutical </font>Pricing and     Reimbursement” for more details</td>
    </tr>
    <tr>
      <td>• <font color="blue">Pharmaceutical </font>research and <font color="blue">development</font> is costly and uncertain</td>
    </tr>
    <tr>
      <td>There are     many <font color="blue"><font color="blue">difficult</font>ies</font> and <font color="blue"><font color="blue">uncertainties</font> inherent</font> in new product <font color="blue">development</font> and     <font color="blue">introduction</font> of <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>New <font color="blue">product candidates</font> that appear promising     in  <font color="blue">development</font>  may fail to reach the market or may have only limited     <font color="blue">commercial success</font> because of efficacy or safety concerns, inability to     obtain <font color="blue">necessary</font> regulatory approvals, limited scope of <font color="blue">approved uses</font>,     <font color="blue"><font color="blue">difficult</font>y</font> or <font color="blue">excessive costs</font> to <font color="blue">manufacture</font>, or <font color="blue">infringement</font> of the patents     or <font color="blue">intellectual property rights</font> of others</td>
    </tr>
    <tr>
      <td>Delays and <font color="blue">uncertainties</font> in the     FDA <font color="blue">approval process</font> and the <font color="blue">approval process</font>es in other countries can     result  in  delays in <font color="blue">product launches</font> and <font color="blue">lost market opportunity</font></td>
    </tr>
    <tr>
      <td>In     addition, it can be very <font color="blue">difficult</font> to <font color="blue">predict sales growth rates</font> of new     products</td>
    </tr>
    <tr>
      <td>•  <font color="blue">Pharmaceutical </font> products  can develop <font color="blue">unexpected safety</font> or efficacy     concerns</td>
    </tr>
    <tr>
      <td><font color="blue">Unexpected </font>safety or <font color="blue">efficacy concerns</font> can arise <font color="blue">with respect</font> to     marketed products, whether or not scientifically justified, leading to     product  recalls,  <font color="blue">withdrawals</font>, or declining sales, as well as product     <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>12       _________________________________________________________________    [60]Table of Contents       • Zyprexa <font color="blue">contributes</font> a major portion of our sales and earnings</td>
    </tr>
    <tr>
      <td>Zyprexa,     our largest-selling product, <font color="blue">contributes</font> a <font color="blue">significant proportion</font> of our     total sales and income, and we believe Zyprexa <font color="blue">will continue</font> to be a major     <font color="blue">contributor</font> to our sales and earnings for <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>An <font color="blue">unexpected steep</font>     and <font color="blue">extended decline</font> in Zyprexa sales (resulting from, for example, an     <font color="blue">unexpected safety</font> or efficacy concern, <font color="blue">regulatory action</font>, or <font color="blue">premature loss</font>     of patent protection) could have a material <font color="blue">adverse impact on</font> our results of     operations, financial condition and liquidity</td>
    </tr>
    <tr>
      <td>• <font color="blue">Regulatory </font><font color="blue">compliance failures could</font> be damaging to the company</td>
    </tr>
    <tr>
      <td>The     marketing,   promotional,  and  pricing  practices  of  <font color="blue">pharmaceutical</font>     <font color="blue">manufacture</font>rs, as well as the manner in which <font color="blue">manufacture</font>rs interact with     purchasers  and <font color="blue">prescribers</font>, are subject to extensive regulation</td>
    </tr>
    <tr>
      <td><font color="blue">Many     </font>companies, including Lilly, have been subject to claims related to these     practices asserted by federal and state <font color="blue">government</font>al authorities and private     payors and consumers</td>
    </tr>
    <tr>
      <td>In particular, See Item 7, “Management’s Discussion and     Analysis —  Legal  and <font color="blue">Regulatory </font>Matters”, for the <font color="blue">discussions</font> of the     US sales and <font color="blue">marketing practices investigations</font></td>
    </tr>
    <tr>
      <td>In addition, regulatory     issues concerning compliance with current <font color="blue">Good Manufacturing Practice </font>(cGMP)     <font color="blue">regulations</font> for <font color="blue">pharmaceutical</font> products can lead to <font color="blue">product recalls</font> and     seizures, interruption of <font color="blue">production leading</font> to <font color="blue">product shortages</font>, and     delays in the approvals of <font color="blue">new products</font> pending resolution of the cGMP     issues</td>
    </tr>
    <tr>
      <td>See Item 1, “Business — Regulation of our Operations”, for more     details</td>
    </tr>
    <tr>
      <td>• We face many product <font color="blue">liability</font> claims today, and future claims will be     largely self-insured</td>
    </tr>
    <tr>
      <td>We are subject to a substantial number of product     <font color="blue">liability</font> claims involving primarily Zyprexa, DES, and thimerosal, and     because of the nature of <font color="blue">pharmaceutical</font> products, it is possible that we     <font color="blue">could become</font> subject to large numbers of product <font color="blue">liability</font> claims for other     products  in  the  future</td>
    </tr>
    <tr>
      <td>See  Item 7,  “Management’s Discussion and</td>
    </tr>
  </tbody>
</table>